Differential Effects of Zanubrutinib and Ibrutinib on Neutrophil Antifungal Functions: Insights from Live-Cell Imaging. [PDF]
Marteyn BS +8 more
europepmc +1 more source
Correction: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study. [PDF]
Zhang Q +14 more
europepmc +1 more source
Clinical improvement of pemphigus-like mucocutaneous disease in a patient with CLL following initiation of zanubrutinib: a case report. [PDF]
Li T, Lu C, Kang T, Tu Y, Sun D.
europepmc +1 more source
Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States. [PDF]
Brown JR +9 more
europepmc +1 more source
Peripheral and central nervous system toxicities of Bruton tyrosine kinase Inhibitors: a real-world pharmacovigilance study. [PDF]
Zhang J.
europepmc +1 more source
Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System. [PDF]
D'Amato M +7 more
europepmc +1 more source
Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc +1 more source
Cardiac adverse event signals of Bruton's tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study. [PDF]
Zhang T, Wang G, Yang X, Li L, Song D.
europepmc +1 more source
A Case of Pseudo-Richter Transformation Following Zanubrutinib Discontinuation in CLL. [PDF]
Laurenti L +14 more
europepmc +1 more source
Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database. [PDF]
Tu J +7 more
europepmc +1 more source

